Adverse Events of Risperidone and Clozapine Combination Therapy on Schizophrenic Patients at Magelang Mental Hospital

Abstract

The adverse drug effect of risperidone and clozapine combination therapy possibly increases the BMI, systolic and diastolic blood pressures of mental victims. This study aimed at determining the relationship between the duration of risperidone and clozapine combination therapy and increase in body mass index (BMI), systolic and diastolic blood pressures of schizophrenic patients. The correlation was obtained using the cohort retrospective method on 59 schizophrenic inpatients at Magelang Mental Hospital from February–May 2019. Participants were grouped into 2 categories, termed <8 and ≥8 weeks with 48 and 11 persons, respectively. Subsequently, patients’ BMI, systolic and diastolic blood pressures were measured during the first day of hospitalization and outpatient consultations, based on NCEP-ATP III cut off-point with the modification of Southeast Asian population’s BMI. Structured questionnaires were used to evaluate calory intake and physical activity as well as generate respondents’ medical records. The bivariate analysis results showed a significant relationship between BMI increase at initial hospitalization and during outpatient consultation on group ≥8 weeks therapy, 22.41±2.98 kg/m2 vs 25.2±6.80 kg/m2 (p=0.023, –2.75 (–5.12–(–0.39)). However, there is no major correlation occurred in systolic 117±11.73 mmHg vs 118±15.42 mmHg (p=0.797, 95%CI –1.07 (–9.41–7.26)) and diastolic blood pressures 76±7.86 mmHg vs 73±8.48 mmHg (p=0.192, 95% CI 3.52 (–1.81–8.86)) for both groups. Furthermore, age, gender, smoking status, dosage, co-medication, calory intake and physical activity indicated no substantial variations, in terms of the increase in BMI, systolic and diastolic blood pressures among two categories.